Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy.
Shuanghui YangJianguo WenHuan LiLing XuYanting LiuNianxi ZhaoZihua ZengJianjun QiWenqi JiangWei HanYouli ZuPublished in: Small (Weinheim an der Bergstrasse, Germany) (2019)
Natural killer (NK) cells are a key component of the innate immune system as they can attack cancer cells without prior sensitization. However, due to lack of cell-specific receptors, NK cells are not innately able to perform targeted cancer immunotherapy. Aptamers are short single-stranded oligonucleotides that specifically recognize their targets with high affinity in a similar manner to antibodies. To render NK cells with target-specificity, synthetic CD30-specific aptamers are anchored on cell surfaces to produce aptamer-engineered NK cells (ApEn-NK) without genetic alteration or cell damage. Under surface-anchored aptamer guidance, ApEn-NK specifically bind to CD30-expressing lymphoma cells but do not react to off-target cells. The resulting specific cell binding of ApEn-NK triggers higher apoptosis/death rates of lymphoma cells compared to parental NK cells. Additionally, experiments with primary human NK cells demonstrate the potential of ApEn-NK to specifically target and kill lymphoma cells, thus presenting a potential new approach for targeted immunotherapy by NK cells.
Keyphrases
- nk cells
- cell cycle arrest
- induced apoptosis
- single cell
- cell therapy
- cell death
- endoplasmic reticulum stress
- oxidative stress
- diffuse large b cell lymphoma
- signaling pathway
- sensitive detection
- risk assessment
- pi k akt
- cancer therapy
- gene expression
- escherichia coli
- genome wide
- label free
- bone marrow
- human health
- candida albicans